What is HC Wainwright’s Forecast for EVAX FY2024 Earnings?

Evaxion Biotech A/S (NASDAQ:EVAX) – Equities researchers at HC Wainwright upped their FY2024 earnings estimates for shares of Evaxion Biotech A/S in a report issued on Monday, February 3rd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.14) for the year, up from their previous estimate of ($0.70). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.13 EPS and FY2028 earnings at $0.06 EPS.

Separately, Lake Street Capital decreased their price objective on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday.

Evaxion Biotech A/S Stock Down 8.6 %

Shares of NASDAQ EVAX opened at $2.99 on Wednesday. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 1 year low of $2.22 and a 1 year high of $23.70. The stock has a market capitalization of $3.50 million, a P/E ratio of -2.06 and a beta of -0.28. The company has a 50-day moving average price of $4.69 and a 200-day moving average price of $10.53.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S at the end of the most recent reporting period. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.